Europe’s medical devices industry saw a drop of 2.56% in deal activity during April 2022, when compared with the last 12-month average, led by Wallaby Medical’s $541.63m acquisition of Phenox, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 38 medical devices industry deals worth $1.1bn were announced for the region in April 2022, against the 12-month average of 39 deals.
Of all the deal types, venture financing saw most activity in April 2022 with 21 transactions, representing a 55.3% share for the region.
In second place was M&A with 12 deals, followed by private equity deals with five transactions, respectively capturing a 31.6% and 13.2% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $883.29m, while venture financing and private equity deals totalled $185.37m and $10.85m, respectively.
Europe medical devices industry deals in April 2022: Top deals
The top five medical devices deals accounted for 84.3% of the overall value during April 2022.
The combined value of the top five medical devices deals stood at $910.25m, against the overall value of $1.1bn recorded for the month.
The top five medical devices industry deals of April 2022 tracked by GlobalData were:
1) Wallaby Medical $541.63m acquisition deal with Phenox
2) The $141.73m acquisition of Aran Biomedical by Integer
3) Cochlear $122.03m acquisition deal with Oticon Medical
4) The $54.73m venture financing of Avi Medical by 3VC Partners,Balderton Capital,Eurazeo,heal.capital Management,Picus Capital and Vorwerk Ventures
5) SD Biosensor $50.14m acquisition deal with Relab
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.